cancer

Two more cancer drugs have been provisionally banned for NHS after it was decided they were too expensive for the potential results.

Royal Bank of Scotland (RBS) has been ordered by the Isle of Man regulator to pay compensation to the family of a man following a mis-selling investigation.

Axa PPP has extended its cancer coverage to include the clinically effective prostate cancer drug rejected for the NHS because it is too expensive.

The government looks set to force through its controversial welfare reforms without giving the House of Lords a chance to readdress the amendments it made.

Cancer charities have slammed the National Institute for Health and Clinical Excellence's (Nice) decision to reject a drug that prolongs the life of prostate cancer suffers for being too expensive.

Defaqto has released its Star Ratings for private medical insurance (PMI) for the first time.

Government ministers will aim to overturn the exclusion of means-testing of cancer patients receiving Employment and Support Allowance (ESA) as the coalition's government's Welfare Reform Bill moves back to the House of Commons.

Bright Grey paid out 91% of critical illness (CI) claims in the last six months of 2011.

Medical insurance brokers have applauded moves by private medical insurance (PMI) providers to remove the limits on cancer coverage for many standard polices.

Axa PPP has removed all cost and time limits for licensed cancer drug treatment for patients on its standard individual and SME plans.